Skip to main content
. 2022 Jan 6;26:8. doi: 10.1186/s13054-021-03879-w

Table 2.

Patient baseline characteristics, pre-ECMO parameters and outcomes in the Supine and Prone group

Baseline characteristics Supine group (n = 575) Prone group (n = 314) p-value
Age, years 52 (41–61) 51 (39–61) 0.506
Sex, female 191 (33.2) 91 (29.0) 0.195
BMI, kg/m2 27 (23–32) 29 (25–34) 0.003
Pre-existing conditions at baseline
 Obesity (BMI ≥ 30) 180 (35.7) 113 (42.3) 0.072
 Hypertension 105 (32.1) 58 (23.9) 0.031
 Diabetes 88 (15.7) 53 (17.3) 0.547
 Chronic respiratory disease 94 (16.8) 37 (12.1) 0.064
 Malignancy 68 (12.1) 28 (9.1) 0.178
 Vascular disease 57 (10.2) 27 (8.8) 0.515
 Chronic heart failure 54 (9.6) 30 (9.8) 0.944
 Chronic renal disease 22 (3.9) 17 (5.5) 0.272
 Chronic liver disease 34 (6.1) 10 (3.2) 0.072
 Immunodeficiency 101 (18.0) 36 (11.7) 0.015
ARDS etiology  < 0.001
 Pulmonary ARDS 405 (70.4) 234 (74.5)
 Extrapulmonary ARDS 58 (10.1) 52 (16.6)
 Other/unknown 112 (19.5) 28 (8.9)
COVID-19 ARDS 11 (1.9) 14 (4.5) 0.028
Mobile ECMO transfer 336 (59.5) 215 (68.5) 0.008
Pre-ECMO variables
 PaO2/FiO2, mmHg 67 (56–80) 66 (55–80) 0.568
 SOFA score 12 (9–16) 10 (8–13)  < 0.001
 Use of nitric oxide 189 (33.3) 91 (29.0) 0.184
 Use of prone positioning 248 (45.1) 180 (57.3) 0.001
 Use of renal replacement therapy 61 (13.7) 31 (11.3) 0.362
 Days of mechanical ventilation before ECMO 3 (1–8) 3 (1–7) 0.632
Outcomes
 ECMO duration, days 8 (4–17) 15 (10–26)  < 0.001
 ECMO successful weaning 326 (57.0) 211 (67.2) 0.003
ICU LOS, days 20 (10–36) 31 (19–48)  < 0.001
 Survivors, n = 449 27 (15–45) 34 (23–49)  < 0.001
 Non-survivors, n = 397 13 (4–26) 23 (16–41)  < 0.001
Time to successful ECMO weaning within 60 days from ECMO start, days 60 (8–60) 28 (12–60) 0.906
ICU mortality, n (%) 298 (52.8) 128 (40.8) 0.001
Hospital mortality, n (%) 306 (54.4) 136 (43.5) 0.002

Data are presented as count (percentage) or median (25th-75th percentile). BMI, body mass index; LOS, length of stay